SWOG clinical trial number
CTSU/C40503

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer

Closed
Phase
Published
Abbreviated Title
ADVANCED: HR+ Randomized, Double-Blind, Placebo-Controlled Phase III, Endocrine or Endocrine +/- Bev
Activated
05/15/2010
Closed
11/15/2011
Participants
CTSU

Research committees

Breast Cancer

Treatment

Leuprolide Acetate Tamoxifen Goserelin Acetate Letrozole Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2022

Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens

J Quintanilha;J Wang;A Sibley;W Xu;O Espin-Garcia;C Jiang;A Etheridge;M Ratain;H-J Lenz;M Bertagnolli;H Kindler;M Dickler;A Venook;J Liu;K Owzar;D Lin;F Innocenti International Journal of Cancer, Jan 15;150(2):279-289. doi: 10.1002/ijc.33810. Epub 2021 Oct 5

PMid: PMID34528705

2020

Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab [note: D. Tripathy in acknowledgements as SWOG study champion]

M Magbanua;O Savenkov;E Asmus;K Ballman;J Scott;J Park;M Dickler;A Partridge;L Carey;E Winer;H Rugo Clinical Cancer Research Jun 25;clincanres.1329.2020. doi: 10.1158/1078-0432.CCR-20-1329. Online ahead of print.

PMid: PMID32586939 | PMC number: PMC750177

2018

Identification of Risk Factors for Toxicity in Patients With Hormone Receptor-Positive Advanced Breast Cancer Treated With Bevacizumab Plus Letrozole: A CALGB 40503 (Alliance) Correlative Study

D Li;L McCall;O Hahn;C Hudis;H Cohen;H Muss;A Jatoi;J Lafky;K Ballman;E Winer;D Tripathy;B Schneider;W Barry;M Dickler;A Hurria Breast Cancer Research and Treatment 171 (2):325-334

PMid: PMID29789969 | PMC number: PMC6076849

2016

A genome-wide association study (GWAS) of survival in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503

F Innocenti;K Owzar;C Jiang;A Sibley;F Mulkey;L Carey;D Tripathy;W Barry;E Winer;C Hudis;H McLeod;M Dickler Journal of Clinical Oncology 34, 2016 (suppl; abstr 538); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session

Identifying risk factors for toxicity in patients with hormone-receptor positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (Alliance) correlative study

D Li;M Dickler;L McCall;O Hahn;C Hudis;H Cohen;HB Muss;K Ballman;W Winer;D Tripathy;C Cirrincione;W Barry;A Hurria Journal of Clinical Oncology 34, 2016 (suppl; abstr 10047); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session

Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance)

MN Dickler;WT Barry;CT Cirrincione;MJ Ellis;ME Moynahan;F Innocenti;A Hurria;HS Rugo;DE Lake;O Hahn;BP Schneider;D Tripathy;LA Carey;EP Winer;C Hudis Journal of Clinical Oncology Aug 1;34(22):2602-2609

PMid: PMID27138575 | PMC number: PMC5012690

2015

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)

M Dickler;WT Barry;CT Cirrincione;M Ellis;M Moynahan;H Rugo;B Schneider;D Tripathy;C Hudis;E Winer Journal of Clinical Oncology 33:5s (suppl; abstr 501); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase